Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study

Diabetes Care

Volumn 31, Issue 3, 2008, Pages 445-447

  Tershakovec, Andrew M ^a   Keane, William F ^a   Zhang, Zhongxin ^a   Lyle, Paulette A ^a   Appel, Gerald B ^b   McGill, Janet B ^c   Parving, Hans Henrik ^d   Cooper, Mark E ^e   Shahinfar, Shahnaz ^a   Brenner, Barry M ^f  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d Mental Health Services CPH   (Denmark)

^e BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ALBUMINURIA; ARTICLE; CONTROLLED STUDY; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; RISK ASSESSMENT; TREATMENT DURATION; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; METABOLISM; RANDOMIZED CONTROLLED TRIAL;

ALBUMINURIA; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY FAILURE, CHRONIC; LOSARTAN; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 44449173148     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc07-0196     Document Type: Article

References (23)

1. Harris K, Thomas M, Short C, Moore R: Assessment of the efficacy of treatment of dyslipidaemia in renal outpatients. J Nephrol 15:263-269, 2002
2. Keane WF, Lyle PA: Kidney disease and cardiovascular disease: implications of dyslipidemia. Cardiol Clin 23:363-372, 2005
3. Attman PO: Progression of renal failure and lipids-is there evidence for a link in humans? Nephrol Dial Transplant 13:545- 547, 1998
4. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in palienls with type 2 diabeles and nephropalhy. N Engl J Med 345:861-869, 2001
5. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972
6. Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R: The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 63:1499-507, 2003
7. Appel GB, Radhakrishnan J, Avram MM, DeFronzo RA, Escobar-Jimenez F, Campos MM, Burgess E, Hille DA, Dickson TZ, Shahinfar S, Brenner BM: Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care 26: 1402-1407, 2003
8. Keane WF, Mulcahy WS, Kasiske BL, Kim Y, O'Donnell MP: Hyperlipidemia and progressive renal disease. Kidney Int Suppl. 31:S41-S48, 1991
9. Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 59: 260-269, 2001
10. Tonelli M, Moyé L, Sacks FM, Cole T, Curhan GC, for the Cholesterol And Recurrent Events (CARE) Trial Investigators: Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 14:1605-1613, 2003
11. Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G, DAIS Investigators: Fenofibrate reduces progression to microalbuminuria over 3 years in a placebocontrolled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 45:485-493, 2005
12. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849-1861, 2005
13. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 patients with diabetes: a randomised placebo-controlled trial. Lancet 361:2005-2016, 2003
14. Campese VM, Bianchi S, Bigazzi R: Hypertension, hyperlipidemia and microalbuminuria. Contrib Nephrol 120:11-21, 1997
15. Campese VM, Bianchi S, Bigazzi R: Is microalbuminuria a predictor of cardiovascular and renal disease in patients with essential hypertension? Curr Opin Nephrol Hypertens 9:143-147, 2000
16. Karådi I, Romics L, Pålos G, Domån J, Kaszås I, Hesz A, Kostner GM: Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin. Clin Chem 35:2121-2123, 1989
17. Kaysen GA: Hyperlipidemia of the nephrotic syndrome. Kidney Int Suppl 31: S8-S15, 1991
18. Keane WF, St. Peter JV, Kasiske BL: Is the aggressive management of hyperlipidemia in nephrotic syndrome mandatory? Kidney Int Suppl 38:S134-S141, 1992
19. Newmark SR, Anderson CF, Donadio JV, Ellefson RD: Lipoprotein profiles in adult nephrotics. Mayo Clin Proc 50:359-364, 1975
20. Kaysen GA: The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol 12:1549-1557, 2001
21. Keane WF: Proteinuria: its clinical importance and role in progressive renal disease. Am J Kidney Dis 35:S97-S105, 2000
22. Moorhead JF, Chan MK, El Nahas M, Varghese Z: Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2:1309-1311, 1982
23. Lin J, Hu FB, Rimm EB, Rifai N, Curhan GC: The association of serum lipids and inflammatory biomarkers with renal function in men with type II diabetes mellitus. Kidney Int 69:336-342, 2006